ATLANTA, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sharecare, the digital health enablement company that helps to improve care quality, drive better outcomes, and lower costs across the healthcare ecosystem, today announced it has won 22 Digital Health Awards in the Health Information Resource Center’s Fall 2025 competition. Now in its 27th year, the semiannual Digital Health Awards honor the best online and virtual health resources for both consumers and professionals. Sharecare earned five Gold awards in the Fall ...

I'm 8 years old, sitting on the edge of an exam table, extremely anxious. You don't have cancer, the doctor tells me. You're too young.But do you know that. I ask. She runs a basic blood test.It's normal. See, you're fine. But where does it say I don't have cancer, though.I ask. She sigh, "This is just the best that we can do." Six months earlier, my grandmother, Caroline, the person everybody said I was just alike, had been diagnosed with stage 4 ovarian cancer. And a few months later, she was gone.At 8, a ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the best digital health stocks to buy now. Wall Street sentiment toward Tempus AI strengthened on November 5, 2025, following the company's Q3 results, with three major firms reiterating positive ratings and updating their targets. Canaccord Genuity kept its Buy rating but trimmed its target slightly from $110 to $95. In its commentary, Canaccord noted that “AI deployment at scale in clinical practice could drive strong long-term revenue growth for Tempus AI.” 10 B ...

GeneDx Holdings Corp. (NASDAQ:WGS) is one of the best digital health stocks to buy now. On October 29, 2025, Guggenheim lifted GeneDx (NASDAQ:WGS) to a $170 price target (Buy) after the company's blow-out Q3 announcement a day earlier. GeneDx had just reported revenue of $116.7 million, up 52% year over year and roughly ~12% above Street; exome and genome revenue reached $98.9 million, up 65%, with exome/genome test volumes up 33%. Gross profitability widened too: adjusted gross margin improved to 74% (GA ...

BrightSpring Health Services, Inc. (NASDAQ:BTSG) is one of the best digital health stocks to buy now. On October 29, one day after the company's release of Q3 results, UBS analyst A.J. Rice. reiterated Buy and lifted their 12-month price target to $42 (from $35), citing a classic “beat-and-raise” quarter and management’s confidence, especially around specialty/infusion momentum carrying into 2026. On October 28, BrightSpring Health Services, Inc. (NASDAQ:BTSG) reported revenue of $3.334 billion (+28.2% Y ...

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best digital health stocks to buy now. Wall Street’s sentiment on GE HealthCare has remained active in recent weeks, with analysts from several firms adjusting their targets as of late October. On October 30, 2025, Morgan Stanley raised its price target on GE HealthCare from $74 to $80 while maintaining an Equal Weight rating. In the accompanying note, analyst Patrick Wood cited solid order trends and backlog strength, stating that the firm’s ho ...

Nov 13, 2025 7:01 AM Eastern Standard Time WELL Health Provides Corporate Update on WELLSTAR Reflecting Organic and Inorganic Growth Wins Ocean eReferrals have delivered measurable improvements in patient care, including a 12% reduction in unnecessary MRIs, a 20% reduction in surgical wait times, and a 35-day decrease in central intake referral processing times. With built-in appropriateness criteria and clinical decision support tools, OceanMD ensures referrals are accurate, necessary, and timely. These be ...

Group 1 - LifeMD, Inc. will participate in the virtual BTIG Digital Health Forum on November 24, 2025, with a panel discussion focused on scalable virtual primary care and obesity health platforms [1] - The management will also be available for one-on-one virtual meetings during the forum [1][2] Group 2 - LifeMD is a leading provider of virtual primary care services, offering telemedicine, laboratory access, and pharmacy services across more than 200 conditions [3] - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, and a state-of-the-art compounding pharmacy to enhance access to quality care [3]

RadNet reported earnings per share (EPS) of $0.20, missing the expected $0.23 but surpassed revenue expectations with $522.9 million.The Digital Health segment saw a significant revenue increase of 51.6%, contributing to the company's overall revenue growth.RadNet's strong liquidity position and improved Adjusted EBITDA margins indicate solid future performance potential.RadNet, Inc. (NASDAQ:RDNT) is a prominent player in the outpatient diagnostic imaging services and digital health solutions sector. The co ...

Industry Overview - The healthcare industry is characterized by continuous innovation in biotechnology, pharmaceuticals, medical devices, and digital health, leading to new treatments and care delivery models that can drive significant growth for leading companies in the coming decades [1] Company Analysis: Pfizer - Pfizer has faced a significant revenue decline due to reduced sales of its COVID-19 products, resulting in a corresponding drop in stock price [4] - The company is focusing on transitioning to a new growth phase through strategic acquisitions, cost-cutting initiatives, and expanding its product pipeline [4][5] - Non-COVID operational revenue is improving, driven by strong performance from products like Vyndaqel, Abrysvo, and Padcev [5] - Pfizer is implementing a cost-realignment program aimed at achieving net savings of $7.2 billion by 2027, with a major focus on oncology following the $43 billion acquisition of Seagen [6] - The current pipeline includes candidates for ulcerative colitis, hemophilia, and obesity, with promising results from Metsera's GLP-1 candidate showing a mean weight loss of up to 14.2% in a phase 2a trial [7] - In the first half of 2025, Pfizer reported net income of $5.9 billion on revenue of $28.4 billion, marking an 86% improvement in net income from the same period in 2024, with Q2 revenue growing by 10% [8] - Despite recent stock price challenges, Pfizer's dividend yield is close to 7%, and the company has a strong history of increasing its dividend [8]